Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 166

Sort by

Sort Order Select

Journal Articles

Subcutaneous daratumumab at home is a safe and effective procedure allowing active treatment of frail patients with multiple myeloma

Gioia De Angelis, Francesca Fazio, Giulio Trapè, Giovanni Manfredi Assanto, Gabriella Tomei, Vincenza Innocenti, Raffaella Randi, Maria Dattolo, Roberta Perazzino, Tania Scancedlla, Roberta Talucci, Michela Tarnani, Alessandro Andriani, Marco Montanaro, Silvia Ciambella, Maria Teresa Petrucci, Claudio Cartoni, Roberto Latagliata

Blood (2025) 146 (Supplement 1): 2806.

https://doi.org/10.1182/blood-2025-2806

Published: 2025

Journal Articles

Personalized prognostic model for multiple myeloma patients using continuous variables

Sonia More', Alfonso Piciocchi, Samuele Confalone, Sara Bringhen, Mattia D'Agostino, Francesca Gay, Michele Cavo, Elena Zamagni, Pieter Sonneveld, Niels W.C.J. Van De Donk, Laura Corvatta, Maria Teresa Petrucci, Francesca Fazio, Mario Boccadoro, Massimo Offidani

Blood (2025) 146 (Supplement 1): 7563.

https://doi.org/10.1182/blood-2025-7563

Published: 2025

Journal Articles

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

Blood (2025) 146 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2025-3977

Published: 2025

Journal Articles

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

Fabio Efficace, Gianluca Gaidano, Pasquale Niscola, Serena Puglia, Francesco Sparano, Katia Codeluppi, Elisabetta Antonioli, Catello Califano, Lajos Floro, Ombretta Annibali, Claudio Fozza, Agostino Tafuri, Patrizio Mazza, Leonardo Potenza, Marco Vignetti, Michele Cavo, Maria Teresa Petrucci

Blood (2025) 146 (Supplement 1): 138.

https://doi.org/10.1182/blood-2025-138

Published: 2025

Journal Articles

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Blood (2025) 146 (Supplement 1): 4002.

https://doi.org/10.1182/blood-2025-4002

Published: 2025

Journal Articles

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with Multiple myeloma: A multicentric experience

Gabriella Tomei, Sonia Morè, Francesca Di Landro, Velia Bongarzoni, Francesca Fazio, Carmine Liberatore, Giusy Antolino, Silvia Gentili, Angela Rago, Laura De Padua, Paola Arcuri, Barbara Anaclerico, Maria Teresa Petrucci, Elena Rossi, Massimo Offidani, Alessandro Andriani, Roberto Latagliata

Blood (2025) 146 (Supplement 1): 5777.

https://doi.org/10.1182/blood-2025-5777

Published: 2025

Journal Articles

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Blood (2025) 146 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2025-6363

Published: 2025

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood (2024) 144 (Supplement 1): 674.

https://doi.org/10.1182/blood-2024-197908

Published: 2024

Journal Articles

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Blood (2024) 144 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2024-204021

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

Blood (2023) 142 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2023-180574

Published: 2023

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Blood (2023) 142 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2023-189193

Published: 2023

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience

Francesca Fazio, Mauro Passucci, Jacopo Micozzi, Silvia Sorella, Chiara Lisi, David Fanciullo, Alfonso Piciocchi, Mahnaz Shafii Bafti, Maurizio Martelli, Maria Gozzer, Maria Teresa Petrucci

Blood (2023) 142 (Supplement 1): 6651.

https://doi.org/10.1182/blood-2023-188780

Published: 2023

Journal Articles

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Massimo Offidani, Michele Cavo, Daniele Derudas, Francesco Di Raimondo, Antonio Cuneo, Luca Baldini, Roberta Della Pepa, Maurizio Musso, Mario Boccadoro, Pellegrino Musto, Maria Teresa Petrucci, Angelo Belotti

Blood (2022) 140 (Supplement 1): 7222–7223.

https://doi.org/10.1182/blood-2022-166399

Published: 2022

Journal Articles

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Blood (2022) 140 (Supplement 1): 10027–10028.

https://doi.org/10.1182/blood-2022-168619

Published: 2022

Journal Articles

Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District

Blood (2022) 140 (Supplement 1): 12549–12550.

https://doi.org/10.1182/blood-2022-166464

Published: 2022

Journal Articles

Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Vittorio Montefusco, Anna Maria Cafro, Gloria Margiotta Casaluci, Francesca Patriarca, Roberto Mina, Mattia D'Agostino, Andrea Capra, Claudia Priola, Anna Benedetta Dalla Palma, Rita Rizzi, Angelo Genua, Maria Teresa Petrucci, Laura Paris, Angelo Belotti, Michele Cavo, Concetta Conticello, Carmelo Carlo-Stella, Mario Boccadoro

Blood (2022) 140 (Supplement 1): 10193–10195.

https://doi.org/10.1182/blood-2022-156691

Published: 2022

Journal Articles

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Blood (2022) 140 (Supplement 1): 7147–7149.

https://doi.org/10.1182/blood-2022-165338

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Subcutaneous daratumumab at home is a safe and effective procedure allowing active treatment of frail patients with multiple myeloma

Personalized prognostic model for multiple myeloma patients using continuous variables

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with Multiple myeloma: A multicentric experience

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District

Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only